Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
about
Profile of secukinumab in the treatment of psoriasis: current perspectivesTreatment challenges in the management of moderate-to-severe plaque psoriasis - role of secukinumabEfficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trialsSecukinumab.Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.Secukinumab (AIN457) for the treatment of psoriasis.Raising Standards for the Evaluation of Future Psoriasis Therapeutics: A Critical Checklist.Secukinumab (AIN-457) for the treatment of Psoriasis.Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch.Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015).Unintended Immunological Consequences of Biologic Therapy.Efficacy and safety of interleukin-17 antagonists in patients with plaque psoriasis: a meta-analysis from phase 3 randomized controlled trials.Cardiovascular and Metabolic Diseases Comorbid with Psoriasis: Beyond the Skin.Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1).Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study.Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single-center experience.Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies.Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan.Pathogenesis of psoriasis and development of treatment.Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups.Recurrent angular cheilitis after secukinumab injections.Quantitative evaluation to efficacy and safety of therapies for psoriasis: A network meta-analysis.Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.
P2860
Q26776303-AEC11B25-B05F-4903-8970-8601E5B71668Q28069819-9050232E-1E0D-4D53-812E-DF71CB637BC0Q35643453-6744D213-74B3-4767-B1DC-123CD5CFEFE4Q36391509-AB46B717-EF23-4B00-8B70-B27821968B43Q37345488-EEA0A05A-BBFF-474E-8223-18770FBD76EFQ38597111-BDE15C95-0CFA-4E17-84F7-CD23944DD5F6Q38658837-9DF03F5A-E194-426E-8F9F-348772C880ADQ38662868-DCA9694D-D458-4B47-941B-9A0987B6BEDAQ38673099-4FC67887-A5A3-4A86-899C-35ED570BA9CAQ38764424-71EFB1E2-DBC4-48A7-A34B-BA0036627472Q38856226-9EA8F84C-37A8-4C80-AFE9-71D69BA736B3Q38871098-B2799364-42D7-40AD-BAF0-3B939B42D9B3Q39096719-F0D44655-BE78-4E4B-9067-F4A3D5455CB0Q39412708-26E844D1-3AF9-4E72-AB65-E67B0A28FFDFQ39965665-BB141C99-6C95-4483-97B3-C1E34E383E2EQ40132474-23F0BC34-CD7F-4C5A-9F24-33A18B4E6637Q40164166-25BAEE33-DB4B-49FC-B468-76DA1C3920AFQ40217411-C96B9799-327F-4CAA-9ECE-AAFF6A3ED54AQ47260366-C8A6712A-EFBF-47CE-9B20-294C9D27D3DFQ47342126-80327217-6A2F-4E8E-9CBC-ED4A5EEB1CF1Q47346793-C04B67D9-A7F6-4162-9F57-C3312EE9D188Q48023865-B68BE8EF-1BB6-49CF-BB36-1A310B5EC12AQ48144635-86DC6698-4BEC-4259-9637-B573B3A129A9Q48170767-CAFD999D-F16E-4873-A5FD-63E3FC38BAB3Q48267976-F28A1C9E-A39F-495C-96F7-C1A5EC2D18B5Q49963125-C245FB19-2F12-4035-943C-780B2ED49DF7Q49985388-E9555CFB-8B97-4B10-9A48-71BF324FE362
P2860
Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Secukinumab efficacy and safet ...... ebo-controlled, phase 3 study.
@en
type
label
Secukinumab efficacy and safet ...... ebo-controlled, phase 3 study.
@en
prefLabel
Secukinumab efficacy and safet ...... ebo-controlled, phase 3 study.
@en
P2093
P2860
P356
P1476
Secukinumab efficacy and safet ...... ebo-controlled, phase 3 study.
@en
P2093
Akimichi Morita
Alexander Karpov
Charis Papavassilis
ERASURE Study Japanese subgroup
Hidemi Nakagawa
Hidetoshi Takahashi
Mamitaro Ohtsuki
Masatoshi Abe
Noriko Seko
Tomohiro Shima
P2860
P304
P356
10.1111/1346-8138.12668
P577
2014-10-30T00:00:00Z